Bristol-Myers Squibb Renews License for Ingenuity Systems Software | GenomeWeb
NEW YORK (GenomeWeb News) – Bristol-Myers Squibb has renewed its license for Ingenuity Systems’ pathway analysis software for use in genomics and proteomics research aimed at advancing its drug discovery programs, Ingenuity said today.
 
Under the agreement, Bristol-Myers Squibb gains enterprise-wide access to the Ingenuity Pathways Analysis software for modeling, visualization, and interpretation of genomics and proteomics data. BMS has been an Ingenuity customer since 2004.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.